Literature DB >> 32276276

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Ramya Ramaswami1, Kathryn Lurain1, Cody J Peer2, Anna Serquiña1, Victoria Wang1, Anaida Widell1, Priscila Goncalves1, Seth M Steinberg3, Vickie Marshall4, Jomy George5, William D Figg2, Denise Whitby4, Joseph Ziegelbauer1, Thomas S Uldrick1, Robert Yarchoan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32276276      PMCID： PMC7316216          DOI： 10.1182/blood.2019004602

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  19 in total

1.  Serum viral interleukin-6 in AIDS-related multicentric Castleman disease.

Authors:  Y Aoki; G Tosato; T W Fonville; S Pittaluga
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

2.  Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients.

Authors:  Alessia Dalla Pria; David Pinato; Jennifer Roe; Kikeri Naresh; Mark Nelson; Mark Bower
Journal:  Blood       Date:  2017-01-31       Impact factor: 22.113

3.  Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.

Authors:  Misato Hashizume; Masahiko Mihara
Journal:  Rheumatol Int       Date:  2008-09-20       Impact factor: 2.631

4.  Emergence of Kaposi's Sarcoma Herpesvirus-Associated Complications Following Corticosteroid Use in TB-IRIS.

Authors:  Maura Manion; Thomas Uldrick; Mark N Polizzotto; Virginia Sheikh; Gregg Roby; Kathryn Lurain; Dorinda Metzger; JoAnn M Mican; Alice Pau; Andrea Lisco; Elizabeth Laidlaw; Dima A Hammoud; Denise Whitby; Robert Yarchoan; Irini Sereti
Journal:  Open Forum Infect Dis       Date:  2018-10-12       Impact factor: 3.835

5.  Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus.

Authors:  Y Aoki; M Narazaki; T Kishimoto; G Tosato
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

6.  HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice.

Authors:  Jan Suthaus; Christiane Stuhlmann-Laeisz; Van S Tompkins; Timothy R Rosean; Wolfram Klapper; Giovanna Tosato; Siegfried Janz; Jürgen Scheller; Stefan Rose-John
Journal:  Blood       Date:  2012-04-09       Impact factor: 22.113

7.  Rituximab therapy for HIV-associated Castleman disease.

Authors:  Anne-Geneviève Marcelin; Laurent Aaron; Christine Mateus; Emmanuel Gyan; Isabelle Gorin; Jean-Paul Viard; Vincent Calvez; Nicolas Dupin
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

8.  Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.

Authors:  Tom Powles; Justin Stebbing; Silvia Montoto; Mark Nelson; Brian Gazzard; Chloe Orkin; Andy Webb; Mark Bower
Journal:  Blood       Date:  2007-12-01       Impact factor: 22.113

9.  Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.

Authors:  Laurence Gérard; Alice Bérezné; Lionel Galicier; Véronique Meignin; Martine Obadia; Nathalie De Castro; Christine Jacomet; Renaud Verdon; Isabelle Madelaine-Chambrin; Emmanuelle Boulanger; Sylvie Chevret; Felix Agbalika; Eric Oksenhendler
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 10.  Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.

Authors:  Kathryn Lurain; Robert Yarchoan; Thomas S Uldrick
Journal:  Hematol Oncol Clin North Am       Date:  2018-02       Impact factor: 3.722
View more
  15 in total

Review 1.  Activation and Evasion of Innate Immunity by Gammaherpesviruses.

Authors:  Philip T Lange; Maria C White; Blossom Damania
Journal:  J Mol Biol       Date:  2021-08-23       Impact factor: 5.469

Review 2.  Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on.

Authors:  Ramya Ramaswami; Kathryn Lurain; Robert Yarchoan
Journal:  J Clin Oncol       Date:  2021-12-10       Impact factor: 44.544

Review 3.  Immunotherapy for KSHV-associated diseases.

Authors:  Kathryn Lurain; Robert Yarchoan; Ramya Ramaswami
Journal:  Curr Opin Virol       Date:  2022-07-05       Impact factor: 7.121

4.  Early Experience With Interleukin-6 Receptor Antagonists in Patients With COVID-19 Admitted to a Community Hospital.

Authors:  Kyle Manning; Chris Whitman; Lindsey Hohmann; Jessica Tubbs; Darrell Childress; Jose A Leon de la Rocha
Journal:  J Pharm Technol       Date:  2022-07-04

Review 5.  Castleman disease.

Authors:  Antonino Carbone; Margaret Borok; Blossom Damania; Annunziata Gloghini; Mark N Polizzotto; Raj K Jayanthan; David C Fajgenbaum; Mark Bower
Journal:  Nat Rev Dis Primers       Date:  2021-11-25       Impact factor: 65.038

6.  Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases.

Authors:  Ramya Ramaswami; Kathryn Lurain; Mark N Polizzotto; Irene Ekwede; Kirsta Waldon; Seth M Steinberg; Ralph Mangusan; Anaida Widell; Adam Rupert; Jomy George; Priscila H Gonçalves; Vickie A Marshall; Denise Whitby; Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe; Richard F Little; Thomas S Uldrick; Robert Yarchoan
Journal:  Blood Adv       Date:  2021-03-23

Review 7.  KSHV/HHV8-mediated hematologic diseases.

Authors:  Ethel Cesarman; Amy Chadburn; Paul G Rubinstein
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

8.  The Importance of Early Recognition of KSHV-Mediated Syndromes: A Case Report.

Authors:  Nathaniel J Spezia-Lindner; Divya Kondapi; Andrew R DiNardo; Ramya Ramaswami; Elizabeth Chiao; Eva H Clark
Journal:  Am J Med       Date:  2021-05-11       Impact factor: 5.928

Review 9.  COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.

Authors:  Jason D Goldman; Philip C Robinson; Thomas S Uldrick; Per Ljungman
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

Review 10.  Cytokine-Targeted Therapeutics for KSHV-Associated Disease.

Authors:  Nedaa Alomari; Jennifer Totonchy
Journal:  Viruses       Date:  2020-09-28       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.